Impact of Probiotics for Reducing Infections in Veterans (IMPROVE): Study protocol for a double-blind, randomized controlled trial to reduce carriage of Staphylococcus aureus

Contemporary Clinical Trials

Volumn 52, Issue , 2017, Pages 39-45

  Eggers, Shoshannah ^a,b   Barker, Anna ^b   Valentine, Susan ^a   Hess, Timothy ^a,b   Duster, Megan ^b   Safdar, Nasia ^a,b,c  

^a WILLIAM S MIDDLETON MEMORIAL VETERANS HOSPITAL   (United States)

^b UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

^c University of Wisconsin Health   (United States)

Author keywords

Clinical trial; Lactobacilli; MRSA; Probiotics; Staphylococcus aureus; Veterans

Indexed keywords

PLACEBO; PROBIOTIC AGENT;

ADULT; ARTICLE; BACTEREMIA; BACTERIAL COLONIZATION; BLOOD ANALYSIS; BLOOD SAMPLING; CLINICAL EVALUATION; CLINICAL PROTOCOL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; FECES ANALYSIS; FEMALE; GASTROINTESTINAL INFECTION; GASTROINTESTINAL TRACT; HOSPITAL PATIENT; HUMAN; LACTOBACILLUS RHAMNOSUS; LEUKOCYTE; MAJOR CLINICAL STUDY; MALE; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; NOSE SMEAR; OUTCOME ASSESSMENT; OUTPATIENT CARE; PATIENT COMPLIANCE; PHAGOCYTOSIS; PHASE 2 CLINICAL TRIAL; POLYMORPHONUCLEAR CELL; RANDOMIZED CONTROLLED TRIAL; SCREENING TEST; STAPHYLOCOCCUS AUREUS; STAPHYLOCOCCUS INFECTION; VETERAN; VETERANS HEALTH; CLINICAL TRIAL; GOVERNMENT; HETEROZYGOTE; UNITED STATES;

CARRIER STATE; DOUBLE-BLIND METHOD; HUMANS; LACTOBACILLUS RHAMNOSUS; PROBIOTICS; STAPHYLOCOCCAL INFECTIONS; STAPHYLOCOCCUS AUREUS; UNITED STATES; UNITED STATES DEPARTMENT OF VETERANS AFFAIRS; VETERANS;

EID: 84994876885     PISSN: 15517144     EISSN: 15592030     Source Type: Journal    
DOI: 10.1016/j.cct.2016.11.004     Document Type: Article

References (61)

1. [1] Klevens, R., Morrison, M.A., Nadle, J., et al. Invasive methicillin-resistant staphylococcus aureus infections in the United States. JAMA 298:15 (2007), 1763–1771, 10.1001/jama.298.15.1763.
2. [2] P R, V., J, M., A comparative analysis of community acquired and hospital acquired methicillin resistant Staphylococcus aureus. J Clin Diagn Res JCDR. 7:7 (2013), 1339–1342, 10.7860/JCDR/2013/5302.3139.
3. [3] Huang, H., Flynn, N.M., King, J.H., Monchaud, C., Morita, M., Cohen, S.H., Comparisons of community-associated methicillin-resistant Staphylococcus aureus (MRSA) and hospital-associated MSRA infections in Sacramento, California. J Clin Microbiol. 44:7 (2006), 2423–2427, 10.1128/JCM.00254-06.
4. [4] Malani, P.N., National burden of invasive methicillin-resistant staphylococcus aureus infection. JAMA 311:14 (2014), 1438–1439, 10.1001/jama.2014.1666.
5. [5] Perl, T.M., Cullen, J.J., Wenzel, R.P., et al. Intranasal mupirocin to prevent postoperative Staphylococcus aureus infections. N. Engl. J. Med. 346:24 (2002), 1871–1877, 10.1056/NEJMoa003069.
6. [6] Wenzel, R.P., Perl, T.M., The significance of nasal carriage of Staphylococcus aureus and the incidence of postoperative wound infection. J Hosp Infect. 31:1 (1995), 13–24, 10.1016/0195-6701(95)90079-9.
7. [7] Kluytmans J, Belkum A van, Verbrugh H. Nasal carriage of Staphylococcus aureus: epidemiology, underlying mechanisms, and associated risks. Clin. Microbiol. Rev. 1997;10(3):505–520.
8. [8] Perl, T.M., Golub, J.E., New approaches to reduce Staphylococcus aureus nosocomial infection rates: Treating S. aureus nasal carriage. Ann Pharmacother. 32:1 (1998), S7–S16, 10.1177/106002809803200104.
9. [9] Eveillard, M., de Lassence, A., Lancien, E., Barnaud, G., Ricard, J., Joly-Guillou, M., Evaluation of a strategy of screening multiple anatomical sites for methicillin-resistant Staphylococcus aureus at admission to a teaching hospital. Infect. Control Hosp. Epidemiol. 27:2 (2006), 181–184, 10.1086/500627.
10. [10] El-Bouri, K., El-Bouri, W., Screening cultures for detection of methicillin-resistant Staphylococcus aureus in a population at high risk for MRSA colonisation: identification of optimal combinations of anatomical sites. Libyan J Med., 8(0), 2013 http://www.libyanjournalofmedicine.net/index.php/ljm/article/view/22755 (Accessed May 26, 2016).
11. [11] Matheson, A., Christie, P., Stari, T., et al. Nasal swab screening for methicillin-resistant Staphylococcus aureus—how well does it perform? A cross-sectional study. Infect. Control Hosp. Epidemiol. 33:8 (2012), 803–808, 10.1086/666639.
12. [12] von Eiff, C., Becker, K., Machka, K., Stammer, H., Peters, G., Nasal carriage as a source of Staphylococcus aureus bacteremia. N. Engl. J. Med. 344:1 (2001), 11–16, 10.1056/NEJM200101043440102.
13. [13] Muder, R.R., Brennen, C., Wagener, M.M., et al. Methicillin-resistant staphylococcal colonization and infection in a long -term care facility. Ann. Intern. Med., 114(2), 1991, 107.
14. [14] Roghmann, M.-C., Siddiqui, A., Plaisance, K., Standiford, H., MRSA colonization and the risk of MRSA bacteraemia in hospitalized patients with chronic ulcers. J Hosp Infect. 47:2 (2001), 98–103, 10.1053/jhin.2000.0903.
15. [15] Dupeyron, C., Campillo, B., Mangeney, N., Bordes, M., Richardet, J., Leluan, G., Carriage of Staphylococcus aureus and of gram-negative bacilli resistant to third-generation Cephalosporins in cirrhotic patients: a prospective assessment of hospital-acquired infections. Infect. Control Hosp. Epidemiol. 22:7 (2001), 427–432, 10.1086/501929.
16. [16] Pacio, G.A., Visintainer, P., Maguire, G., Wormser, G.P., Raffalli, J., Montecalvo, M.A., Natural history of colonization with vancomycin-resistant enterococci, methicillin-resistant Staphylococcus aureus, and resistant Gram-negative bacilli among long-term–care facility residents. Infect. Control Hosp. Epidemiol. 24:4 (2003), 246–250, 10.1086/502201.
17. [17] Garrouste-Orgeas, M., Timsit, J., Kallel, H., et al. Colonization with methicillin-resistant Staphylococcus aureus in ICU patients: morbidity, mortality, and glycopeptide use. Infect. Control Hosp. Epidemiol. 22:11 (2001), 687–692, 10.1086/501846.
18. [18] Campillo, B., Dupeyron, C., Richardet, J.P., Epidemiology of hospital-acquired infections in cirrhotic patients: effect of carriage of methicillin-resistant Staphylococcus aureus and influence of previous antibiotic therapy and norfloxacin prophylaxis. Epidemiol. Infect. 127:3 (2001), 443–450.
19. [19] Aarts, M.-A.W.M., Hancock, J.N., Heyland, D.M., McLeod, R.S.M., Marshall, J.C.M., Empiric antibiotic therapy for suspected ventilator-associated pneumonia: a systematic review and meta-analysis of randomized trials. Crit. Care Med. 36:1 (2008), 108–117, 10.1097/01.CCM.0000297956.27474.9D.
20. [20] Pujol, M., Peña, C., Pallares, R., et al. Nosocomial Staphylococcus aureus bacteremia among nasal carriers of methicillin-resistant and methicillin-susceptible strains. Am. J. Med. 100:5 (1996), 509–516, 10.1016/S0002-9343(96)00014-9.
21. [21] Longfield, J.N., Townsend, T.R., Cruess, D.F., et al. Methicillin-resistant Staphylococcus aureus (MRSA): risk and outcome of colonized vs infected patients. Infect. Control. 6:11 (1985), 445–450.
22. [22] Coello, R., Glynn, J.R., Gaspar, C., Picazo, J.J., Fereres, J., Risk factors for developing clinical infection with methicillin-resistant Staphylococcus aureus (MRSA) amongst hospital patients initially only colonized with MRSA. J Hosp Infect. 37:1 (1997), 39–46, 10.1016/S0195-6701(97)90071-2.
23. [23] Hagiwara, S., Miwa, A., Yoshida, M., et al. Methicillin-resistant Staphylococcus aureus: colonization and development of infection in patients with haematological disorders. Eur. J. Haematol. 55:4 (1995), 267–271, 10.1111/j.1600-0609.1995.tb00272.x.
24. [24] Fierobe, L., Decré, D., Mùller, C., et al. Methicillin-resistant Staphylococcus aureus as a causative agent of postoperative intra-abdominal infection: relation to nasal colonization. Clin. Infect. Dis. 29:5 (1999), 1231–1238.
25. [25] Jernigan, J.A., Titus, M.G., Gröschel, D.H.M., Getchell-White, S.I., Farr, B.M., Effectiveness of contact isolation during a hospital outbreak of methicillin resistant Staphylococcus aureus. Am. J. Epidemiol. 143:5 (1996), 496–504.
26. [26] Girou, E., Pujade, G., Legrand, P., Cizeau, F., Brun-Buisson, C., Selective screening of carriers for control of methicillin-resistant Staphylococcus aureus (MRSA) in high-risk hospital areas with a high level of endemic MRSA. Clin. Infect. Dis. 27:3 (1998), 543–550, 10.1086/514695.
27. [27] Mest, D.R., Wong, D.H.P., Shimoda, K.J.R., Mulligan, M.E., Wilson, S.E., Nasal colonization with methicillin-resistant Staphylococcus aureus on admission to the surgical intensive care unit increases the risk of infection. Anesth. Analg. 78:4 (1994), 644–650.
28. [28] Safdar, N., Bradley, E.A., The risk of infection after nasal colonization with Staphylococcus aureus. Am. J. Med. 121:4 (2008), 310–315, 10.1016/j.amjmed.2007.07.034.
29. [29] Davis, K.A., Stewart, J.J., Crouch, H.K., Florez, C.E., Hospenthal, D.R., Methicillin-resistant Staphylococcus aureus (MRSA) nares colonization at hospital admission and its effect on subsequent MRSA infection. Clin. Infect. Dis. 39:6 (2004), 776–782.
30. [30] Levy, S.B., The challenge of antibiotic resistance. Sci. Am. 278:3 (1998), 32–39.
31. [31] Levy, S.B., Marshall, B., Antibacterial resistance worldwide: causes, challenges and responses. Nat. Med. 10 (2004), S122–S129, 10.1038/nm1145.
32. [32] Chopra, I., Roberts, M., Tetracycline antibiotics: mode of action, applications, molecular biology, and epidemiology of bacterial resistance. Microbiol. Mol. Biol. Rev. 65:2 (2001), 232–260, 10.1128/MMBR.65.2.232-260.2001.
33. [33] Glück, U., Gebbers, J.-O., Ingested probiotics reduce nasal colonization with pathogenic bacteria (Staphylococcus aureus, Streptococcus pneumoniae, and β-hemolytic streptococci). Am. J. Clin. Nutr. 77:2 (2003), 517–520.
34. [34] Gill, H.S., Rutherfurd, K.J., Cross, M.L., Dietary probiotic supplementation enhances natural killer cell activity in the elderly: an investigation of age-related immunological changes. J. Clin. Immunol. 21:4 (2001), 264–271, 10.1023/A:1010979225018.
35. [35] Gill, H.S., Rutherfurd, K.J., Probiotic supplementation to enhance natural immunity in the elderly: effects of a newly characterized immunostimulatory strain Lactobacillus rhamnosus HN001 (DR20™) on leucocyte phagocytosis. Nutr. Res. 21:1–2 (2001), 183–189, 10.1016/S0271-5317(00)00294-3.
36. [36] Tannock, G.W., Munro, K., Harmsen, H.J.M., Welling, G.W., Smart, J., Gopal, P.K., Analysis of the fecal microflora of human subjects consuming a probiotic product containing Lactobacillus rhamnosusDR20. Appl. Environ. Microbiol. 66:6 (2000), 2578–2588, 10.1128/AEM.66.6.2578-2588.2000.
37. [37] Gopal, P.K., Prasad, J., Smart, J., Gill, H.S., In vitro adherence properties of Lactobacillus rhamnosus DR20 and Bifidobacterium lactis DR10 strains and their antagonistic activity against an enterotoxigenic Escherichia coli. Int. J. Food Microbiol. 67:3 (2001), 207–216, 10.1016/S0168-1605(01)00440-8.
38. [38] Cross, M.L., Mortensen, R.R., Kudsk, J., Gill, H.S., Dietary intake of Lactobacillus rhamnosus HN001 enhances production of both Th1 and Th2 cytokines in antigen-primed mice. Med Microbiol Immunol (Berl). 191:1 (2002), 49–53, 10.1007/s00430-002-0112-7.
39. [39] Gill, H.S., Rutherfurd, K.J., Immune enhancement conferred by oral delivery of Lactobacillus rhamnosus HN001 in different milk-based substrates. J Dairy Res. 68:4 (2001), 611–616, 10.1017/S0022029901005155.
40. [40] Sheih, Y.-H., Chiang, B.-L., Wang, L.-H., Liao, C.-K., Gill, H.S., Systemic immunity-enhancing effects in healthy subjects following dietary consumption of the lactic acid bacterium Lactobacillus rhamnosus HN001. J. Am. Coll. Nutr. 20:2 (2001), 149–156, 10.1080/07315724.2001.10719027.
41. [41] Gill, H.S., Rutherfurd, K.J., Cross, M.L., Gopal, P.K., Enhancement of immunity in the elderly by dietary supplementation with the probiotic Bifidobacterium lactis HN019. Am. J. Clin. Nutr. 74:6 (2001), 833–839.
42. [42] Österlund, P., Ruotsalainen, T., Korpela, R., et al. Lactobacillus supplementation for diarrhoea related to chemotherapy of colorectal cancer: a randomised study. Br. J. Cancer 97:8 (2007), 1028–1034, 10.1038/sj.bjc.6603990.
43. [43] M, M., E, L., D, L., et al. Prevention of febrile neutropenia in cancer patients by probiotic strain Enterococcus faecium M-74. Pilot study phase I. Neoplasma 52:2 (2004), 159–164.
44. [44] Mego, M., Koncekova, R., Mikuskova, E., et al. Prevention of febrile neutropenia in cancer patients by probiotic strain Enterococcus faecium M-74. Phase II study. Support Care Cancer. 14:3 (2005), 285–290, 10.1007/s00520-005-0891-7.
45. [45] Heiser, C.R., Ernst, J.A., Barrett, J.T., French, N., Schutz, M., Dube, M.P., Probiotics, soluble fiber, and L-glutamine (GLN) reduce nelfinavir (NFV)or lopinavir/ritonavir (LPV/r)-related diarrhea. J Int Assoc Physicians AIDS Care JIAPAC. 3:4 (2004), 121–129, 10.1177/154510970400300403.
46. [46] Cunningham-Rundles, S., Ahrné, S., Bengmark, S., et al. Probiotics and immune response. Am. J. Gastroenterol. 95:1, Supplement 1 (2000), S22–S25, 10.1016/S0002-9270(99)00813-8.
47. [47] Timsit, J.F., Cheval, C., Gachot, B., et al. Usefulness of a strategy based on bronchoscopy with direct examination of bronchoalveolar lavage fluid in the initial antibiotic therapy of suspected ventilator-associated pneumonia. Intensive Care Med. 27:4 (2001), 640–647, 10.1007/s001340000840.
48. [48] Salminen, M.K., Tynkkynen, S., Rautelin, H., et al. The efficacy and safety of probiotic Lactobacillus rhamnosus GG on prolonged, noninfectious diarrhea in HIV patients on antiretroviral therapy: a randomized, placebo-controlled. Crossover Study. HIV Clin Trials. 5:4 (2004), 183–191, 10.1310/6F83-N39Q-9PPP-LMVV.
49. [49] Pawłowska, J., Klewicka, E., Czubkowski, P., et al. Effect of lactobacillus casei DN-114001 application on the activity of fecal enzymes in children after liver transplantation. Transplant. Proc. 39:10 (2007), 3219–3221, 10.1016/j.transproceed.2007.03.101.
50. [50] Zhou, J.S., Shu, Q., Rutherfurd, K.J., Prasad, J., Gopal, P.K., Gill, H.S., Acute oral toxicity and bacterial translocation studies on potentially probiotic strains of lactic acid bacteria. Food Chem. Toxicol. 38:2–3 (2000), 153–161, 10.1016/S0278-6915(99)00154-4.
51. [51] Zhou, J.S., Shu, Q., Rutherfurd, K.J., et al. Safety assessment of potential probiotic lactic acid bacterial strains Lactobacillus rhamnosus HN001, Lb. acidophilus HN017, and Bifidobacterium lactis HN019 in BALB/c mice. Int. J. Food Microbiol. 56:1 (2000), 87–96, 10.1016/S0168-1605(00)00219-1.
52. [52] Zhou, J.S., Gopal, P.K., Gill, H.S., Potential probiotic lactic acid bacteria Lactobacillus rhamnosus (HN001), Lactobacillus acidophilus (HN017) and Bifidobacterium lactis (HN019) do not degrade gastric mucin in vitro. Int. J. Food Microbiol. 63:1–2 (2001), 81–90, 10.1016/S0168-1605(00)00398-6.
53. [53] Shu Q, Zhou JS, J. Rutherfurd K, et al. Probiotic lactic acid bacteria (Lactobacillus acidophilus HN017, Lactobacillus rhamnosus HN001 and Bifidobacterium lactis HN019) have no adverse effects on the health of mice. Int. Dairy J. 1999;9(11):831–836. doi: 10.1016/S0958-6946(99)00154-5.
54. [54] Manley, K.J., Fraenkel, M.B., Mayall, B.C., DA, P., Probiotic treatment of vancomycin-resistant enterococci: a randomised controlled trial. Med. J. Aust., 186(9), 2007 https://www.mja.com.au/journal/2007/186/9/probiotic-treatment-vancomycin-resistant-enterococci-randomised-controlled-trial (Accessed May 26, 2016).
55. [55] Gill, H.S., Rutherfurd, K.J., Gopal, P.K., Dietary probiotic supplementation to enhance cellular immunity in the elderly. Br. J. Biomed. Sci. 58:2 (2001), 94–96.
56. [56] Gill, H.S., Shu, Q., Lin, H., Rutherfurd, K.J., Cross, M.L., Protection against translocating Salmonella typhimurium infection in mice by feeding the immuno-enhancing probiotic Lactobacillus rhamnosus strain HN001. Med Microbiol Immunol (Berl). 190:3 (2001), 97–104, 10.1007/s004300100095.
57. [57] Gill, H.S., Rutherfurd, K.J., Prasad, J., Gopal, P.K., Enhancement of natural and acquired immunity by Lactobacillus rhamnosus (HN001), Lactobacillus acidophilus (HN017) and Bifidobacterium lactis (HN019). Br. J. Nutr. 83:2 (2000), 167–176, 10.1017/S0007114500000210.
58. [58] Isolauri, E., Sütas, Y., Kankaanpää, P., Arvilommi, H., Salminen, S., Probiotics: effects on immunity. Am. J. Clin. Nutr. 73:2 (2001), 444s–450s.
59. [59] Paineau, D., Carcano, D., Leyer, G., et al. Effects of seven potential probiotic strains on specific immune responses in healthy adults: a double-blind, randomized, controlled trial. FEMS Immunol. Med. Microbiol. 53:1 (2008), 107–113, 10.1111/j.1574-695X.2008.00413.x.
60. [60] de Vrese, M., Winkler, P., Rautenberg, P., et al. Probiotic bacteria reduced duration and severity but not the incidence of common cold episodes in a double blind, randomized, controlled trial. Vaccine 24:44–46 (2006), 6670–6674, 10.1016/j.vaccine.2006.05.048.
61. [61] Shu, Q., Gill, H.S., Immune protection mediated by the probiotic Lactobacillus rhamnosus HN001 (DR20™) against Escherichia coli O157:H7 infection in mice. FEMS Immunol. Med. Microbiol. 34:1 (2002), 59–64, 10.1111/j.1574-695X.2002.tb00603.X.